Aptiv Q4 Revenue Up 5% and EPS Beats, Price Targets Lifted to $106

APTVAPTV

Aptiv's Q4 revenue rose to $5.153B and adjusted EPS hit $1.86, surpassing estimates by $48M and $0.01 respectively, with 8% North America and 12% South America growth. It guided Q1 net sales of $4.95–5.15B and adjusted EPS of $1.55–1.75, prompting price target hikes to $102 and $106.

1. Upbeat Q4 Financial Performance

Aptiv reported U.S. GAAP revenue of $5.153 billion for the fourth quarter, up from $4.907 billion a year earlier. On an adjusted basis, revenue rose 3%, driven by regional gains of 8% in North America and 12% in South America, partially offset by 1% declines in both Europe and Asia. Adjusted EPS came in at $1.86, narrowly surpassing the consensus estimate of $1.85 and up from $1.75 in the year-ago period. The company’s adjusted operating income was $607 million, compared with $623 million a year ago, reflecting benefits from cost-reduction measures that were largely offset by $66 million in higher commodity and currency headwinds.

2. 2026 Guidance Highlights Mixed Outlook

For Q1 2026, Aptiv projected net sales between $4.950 billion and $5.150 billion and adjusted EPS of $1.55 to $1.75, below consensus estimates of $1.92. Full-year 2026 guidance anticipates net sales of $21.120 billion to $21.820 billion and adjusted EPS of $8.15 to $8.75, modestly above last year’s $8.46 projection. GAAP diluted EPS are forecast at $5.75 to $6.35 versus estimates of $7.21. The company reiterated its plan to complete the spin-off of its Electrical Distribution Systems business as Versigent, intended to create two independent, capital-flexible entities.

3. Analysts Lift Price Targets Following Results

In response to the quarter’s outperformance, Wells Fargo’s Colin Langan maintained an Overweight rating and raised his price target from $99 to $102, citing stronger North American penetration in advanced safety systems. Oppenheimer’s Colin Rusch kept an Outperform rating and lifted his target from $102 to $106, highlighting resilient adjusted operating margins and anticipated benefits from the forthcoming Versigent separation.

Sources

SBZZB
+3 more